10-K: Veeva Systems Reports Strong FY26 Growth, Strategic AI Push

Veeva Systems Inc. reported robust financial results for fiscal year 2026, driven by expanding subscription revenues and strategic investments in AI and R&D solutions for the global life sciences industry.

Summary

• Total revenues for the fiscal year ended January 31, 2026, increased by 16% to $3,195 million, up from $2,747 million in the prior fiscal year.
• Subscription revenues grew by 17% to $2,684 million, compared to $2,285 million in the previous fiscal year.
• Net income for the fiscal year was $909 million, a significant increase from $714 million in the prior year.
• Operating income reached $916 million, up from $691 million in the fiscal year ended January 31, 2025.
• The customer base expanded to 1,552 as of January 31, 2026, from 1,477 in the previous year.
• R&D and Quality Solutions subscription revenue increased by $247 million, while Commercial Solutions subscription revenue increased by $153 million.
• Cash, cash equivalents, and short-term investments totaled $6.6 billion as of January 31, 2026.
• The board authorized a share repurchase program of up to $2 billion in January 2026, with $180 million (801,735 shares) repurchased during the fiscal year at an average price of $224.43 per share.
• Veeva acquired Rise Healthcare Tech, Inc. (Ostro) on March 10, 2026, for approximately $100 million in cash and long-term equity retention grants, enhancing its AI-driven chat engagement platform for life sciences.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong performance, marked by robust revenue and net income growth, an expanding customer base, and strategic investments in AI and R&D. The share repurchase program and recent acquisition further underscore a positive outlook, despite inherent competitive and regulatory risks.

Positives

• Total revenues increased by a strong 16% year-over-year to $3,195 million.
• Subscription revenues, the primary revenue driver, grew by 17% year-over-year to $2,684 million.
• Net income saw a substantial increase to $909 million, demonstrating enhanced profitability.
• The customer base expanded to 1,552, indicating continued market penetration and customer acquisition.
• R&D and Quality Solutions are growing as a percentage of total revenues, signaling successful diversification and strength in critical drug development and quality segments.
• The introduction of Veeva AI, with agentic AI for the Veeva Vault platform and industry-specific agents, positions the company at the forefront of technological innovation in life sciences.
• The acquisition of Rise Healthcare Tech, Inc. (Ostro) for $100 million expands AI-driven patient and doctor engagement capabilities.
• A $2 billion share repurchase program was authorized, with $180 million already executed, reflecting confidence in the company's valuation and commitment to shareholder returns.
• The company maintains a strong liquidity position with $6.6 billion in cash, cash equivalents, and short-term investments.
• Management and independent auditors concluded that internal control over financial reporting was effective as of January 31, 2026.

Negatives

• The company faces intense competition in its markets, particularly in CRM from Salesforce and in data cloud from IQVIA, Ipsos Group S.A., and Definitive Health Corp.
• The migration of customers from legacy Veeva CRM (built on Salesforce) to Vault CRM (built on Veeva Vault) could cause business disruptions and potential customer loss, with some large customers already committing to Salesforce's CRM solutions.
• Revenue is relatively concentrated, with the top 10 customers accounting for 28% of total revenues, making the company vulnerable to the loss or non-renewal of these key accounts.
• Reliance on third-party providers like Amazon Web Services and Salesforce for computing infrastructure introduces risks of service disruptions or failures.
• Sales cycles can be long and unpredictable, requiring significant resource investment without guaranteed sales outcomes.
• Operating expenses are expected to increase in the future, primarily due to employee compensation-related costs and investments in R&D and sales and marketing, which may impact profitability.
• Professional services revenues and gross margins are volatile and may not consistently increase.
• The use of open-source software in solutions carries risks, including potential requirements to release proprietary source code or difficulties in complying with license terms.
• Incorporating AI in solutions introduces new risks related to privacy, security, inefficacy, bias, and rapidly evolving legal and regulatory frameworks.

Risks

• Security breaches or unauthorized access to customer data could lead to perceived insecurity, reduced customer use, and significant liabilities.
• Intense competition, particularly in the CRM market during the transition to Vault CRM, could result in customer loss and adverse effects on business and operating results.
• Defects or disruptions in solutions could diminish demand, reduce revenues, and subject the company to substantial liability.
• Failure of newer solutions (including AI technologies) to be successfully adopted by customers would adversely affect revenue growth.
• Revenue concentration within a small number of key customers means the loss or non-renewal of one or more could cause revenue decline.
• Adverse factors affecting the life sciences industry (e.g., regulatory changes, drug pricing, consolidation, funding environment, geopolitical conditions) could negatively impact the company.
• Uncertain macroeconomic and geopolitical factors (e.g., inflation, currency fluctuations, interest rates, conflicts like Russia-Ukraine, Middle East) may cause global economic instability and disrupt the life sciences industry.
• Migration of CRM customers to Vault CRM could cause business disruptions for customers and adversely affect operating results.
• Longer-term revenue growth rates are likely to fluctuate and may decline, and increasing costs may prevent sustaining past profitability levels.
• Reliance on third-party providers (AWS, Salesforce) for computing infrastructure, secure network connectivity, and other technology services means any disruption could adversely affect the business.
• Difficulty attracting and retaining highly skilled employees could adversely affect the business and increase expenses.
• Changing and increasingly complex U.S. and international data privacy and information security regulations (e.g., EU GDPR, UK GDPR, CCPA, HIPAA, PIPL, EU Data Act, NIS2, EU AI Act) may impose additional compliance costs, reduce demand, and lead to significant liabilities.
• Risk of being sued for infringement or misappropriation of third-party intellectual property, potentially leading to significant damages or other harm.
• Acquisitions could divert management's attention, result in stockholder dilution, disrupt operations, and adversely affect operating results.
• Status as a Delaware Public Benefit Corporation (PBC) may not yield anticipated benefits, requires directors to balance stockholder and other stakeholder interests, and may subject the company to legal uncertainty.
• Evolving expectations and disclosure requirements related to environmental, social, and governance (ESG) matters expose the company to risks affecting reputation and performance.
• Common stock price has been and will likely continue to be volatile due to numerous factors, including macroeconomic conditions and industry-specific events.
• Share repurchase program may not enhance long-term shareholder value and reduces cash available for other corporate purposes.
• No intention to pay dividends for the foreseeable future, limiting stockholder returns to stock price changes.
• Provisions in corporate documents and Delaware law might discourage, delay, or prevent a change in control or management.
• Bylaws provide for exclusive forums for certain disputes, potentially limiting stockholders' ability to choose a favorable judicial forum.

Future Outlook

R&D and Quality Solutions revenues are expected to increase as a percentage of both subscription and total revenues in the future. The company anticipates increases in absolute dollars for cost of subscription due to increased usage and continued investment in data solutions, and for cost of professional services and other due to investment in its services organization. Operating expenses, particularly employee compensation-related costs, are also expected to rise, with R&D and sales and marketing expenses specifically projected to increase. General and administrative expenses are expected to decrease in the next fiscal year due to a reduction in litigation settlement-related charges. The One Big Beautiful Bill Act (OBBBA) is expected to increase cash flows from operating activities in future periods, though the specific amount is currently unestimable. The company plans to expand facilities capacity in certain field locations during the fiscal year ending January 31, 2027, and potentially beyond. Management believes existing cash, cash equivalents, and short-term investments will be sufficient to meet working capital and capital expenditure needs for at least the next 12 months. Future capital requirements will depend on various factors including growth rate, product development, and market acceptance. The company may also pursue acquisitions or investments in complementary businesses. No cash dividends are anticipated for the foreseeable future.

Management Comments

• Our public benefit purpose, as reflected in our certificate of incorporation, is to provide products and services that are intended to help make the industries we serve more productive, and to create high-quality employment opportunities in the communities in which we operate.
• We believe that operating as a PBC reflects our core values do the right thing, customer success, employee success, and speed and helps us maintain alignment with the principal industry we serve, life sciences, and its broad goal to improve health and extend lives.
• We believe our compensation and benefits programs are competitive.
• We consider our relations with our employees to be very good.
• We believe that we generally compete favorably on the basis of these factors [competitive factors].
• Our management is responsible for establishing and maintaining adequate internal control over financial reporting... Based on the assessment, our management has concluded that our internal control over financial reporting was effective as of January 31, 2026 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. GAAP.

Industry Context

StockSavvy.ai notes Veeva's continued dominance in the specialized life sciences cloud solutions market, leveraging its deep industry expertise to drive growth. The strategic focus on AI, particularly with Veeva AI Agents, aligns with broader industry trends of digital transformation and automation in healthcare and pharmaceutical sectors. The acquisition of Ostro further strengthens its patient and doctor engagement capabilities, positioning it well against generalist tech providers by offering tailored, compliant solutions. The ongoing migration from Salesforce-based CRM to its proprietary Vault CRM platform is a critical strategic move, aiming to enhance control and differentiation, though it introduces competitive risks from Salesforce itself.

Comparison to Industry Standards

• Veeva's 16% total revenue growth and 17% subscription revenue growth for FY26 are strong within the enterprise software sector, especially for a company of its size, often outpacing the average growth rates of mature SaaS companies.
• Its net income of $909 million and operating income of $916 million demonstrate robust profitability, frequently exceeding the margins of many generalist SaaS providers due to its specialized, high-value niche.
• The company's specialized focus on life sciences allows it to maintain higher customer retention and expand within its niche, contrasting with broader enterprise software companies that face more fragmented competition and often lower customer lifetime values.
• The transition from Salesforce CRM to Vault CRM is a significant undertaking, akin to major platform migrations seen in companies like Adobe moving from perpetual licenses to cloud subscriptions, or Oracle shifting customers to its cloud infrastructure. This move aims for greater control and potentially higher long-term margins, but carries execution risk and direct competition with Salesforce's own life sciences CRM offerings.
• The $2 billion share repurchase program is a substantial capital allocation strategy, comparable to those undertaken by mature, highly profitable tech companies like Apple or Microsoft, signaling confidence in future cash flows and a commitment to shareholder returns, often seen as a sign of financial strength and limited immediate reinvestment opportunities.

Corporate Governance

Legal Proceedings

• A settlement agreement was reached with IQVIA on August 13, 2025, resolving all ongoing litigations between the two companies, with neither party paying damages and all claims dismissed with prejudice.
• Approximately $31 million was paid to law firms with partial contingency fee arrangements related to the IQVIA settlement.
• The company is aware of a non-practicing entity alleging patent infringement.
• The company may be involved in other legal proceedings and claims incident to the ordinary course of business, but none are currently believed to have a material adverse effect on the business, operating results, cash flows, or financial position.

Stakeholder Impact

• Shareholders: Positive impact from strong financial performance, share repurchase program, and strategic growth initiatives. Potential risks from stock price volatility, no future dividends, and the Public Benefit Corporation (PBC) status balancing interests.
• Customers: Benefit from expanding and enhanced cloud solutions, including new AI capabilities, and a continued focus on customer success. Potential disruption during the CRM migration and reliance on third-party infrastructure are noted risks.
• Employees: Positive impact from competitive compensation and benefits, good relations with management, and the 'Work Anywhere' policy offering flexibility. Risks include intense competition for talent and potential challenges in maintaining productivity with remote work.
• Partners: The wind-down period for the Salesforce agreement affects partners utilizing that platform. The company works with systems integrator partners for project delivery.
• Communities: Positive impact from the company's public benefit purpose to create high-quality employment opportunities in the communities where it operates.

Next Steps

• Continue to invest in and grow the business, including developing new solutions and enhancing existing solutions.
• Expand the direct sales organization and global marketing programs.
• Expand the professional services organization.
• Make ongoing investments in technology infrastructure.
• Expand facilities capacity in certain field locations during the fiscal year ending January 31, 2027, and potentially thereafter.
• Evaluate the accounting treatment and complete the preliminary purchase price allocation for the Ostro acquisition.
• Monitor and assess the implications of OECD-related developments to the side-by-side system and the evolving Pillar Two framework for tax.
• Early adopt ASU 2025-06 in the fiscal quarter ended April 30, 2026.
• Evaluate ASU 2024-03 to determine its impact on disclosures.

Key Dates

Recommendation

Veeva Systems demonstrates robust financial health with significant revenue and net income growth, a strong balance sheet, and a clear strategic direction focused on AI innovation and R&D solutions within its specialized life sciences market. The substantial share repurchase program signals management's confidence and commitment to shareholder value. While competitive pressures and the CRM migration present risks, the company's established market leadership, consistent execution, and proactive expansion into new technologies like AI position it for continued long-term success. The acquisition of Ostro further enhances its product ecosystem.

Keywords

Life Sciences, Cloud Solutions, CRM, R&D, Quality Management, Data Cloud, AI, Pharmaceutical, Biotechnology, MedTech, SEC Filing, 10-K, Financial Results, Software, SaaS, Healthcare Technology, Corporate Governance, Risk Management, Share Repurchase, Public Benefit Corporation